Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Dose-finding Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Mild to Moderate Ulcerative Colitis

Name
SPH3127-203
Description
To preliminarily evaluate the clinical efficacy of the renin inhibitor SPH3127 Tablets in patients with mild to moderate ulcerative colitis with placebo as a control and determine the recommended dose.
Trial arms
Trial start
2023-06-19
Estimated PCD
2025-02-15
Trial end
2025-02-15
Status
Recruiting
Phase
Early phase I
Treatment
SPH3127 Tablets with Dose A
See Arm description
Arms:
SPH3127 Tablets with Dose A
SPH3127 Tablets with Dose B
See Arm description
Arms:
SPH3127 Tablets with Dose B
SPH3127 Tablets placebo
See Arm description
Arms:
SPH3127 Tablets placebo
Size
108
Primary endpoint
Symptom remission rate
Week8
Endoscopic remission rate
Week8
Eligibility criteria
Inclusion Criteria: 1. Aged 18 - 75 years, male or female; 2. Subjects who have been diagnosed with ulcerative colitis; 3. Subjects who agree to take effective contraceptive measures with their spouses throughout the study period and for up to 12 weeks after the last dose; 4. Subjects who thoroughly learn about the nature, significance, possible benefits, possible inconvenience and potential risks of the trial, understand the study procedures and voluntarily sign the informed consent form prior to their participation in the trial. Exclusion Criteria: 1. Subjects who are diagnosed with Crohn's disease or indeterminate colitis; 2. Subjects with active infections at screening which may, as evaluated by the investigator, cause increased risks for subjects; 3. Subjects who had surgery that might impact the absorption of oral drugs, subjects who will undergo surgery during the study period, subjects who have undergone major surgery before screening, or subjects who have a plan of surgery during the study period; 4. Subjects and lactating women and those who will become pregnant within 6 months after the trial starts; 5. Subjects with a history of drug abuse with clinical significance within 1 year prior to screening; 6. Subjects with other diseases or conditions that the investigator considers unsuitable for this trial.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 108, 'type': 'ESTIMATED'}}
Updated at
2024-04-04

1 organization

1 product

1 indication

Product
SPH3127